Is Swedish Orphan Biovitrum stock a buy?
What Is The Conclusion?
Right now our advanced algorithms say:
Do the analyst corps agree?
Interesting Questions and Easy Answers!
We cannot find any recorded dividends paid in our systems.
Sorry, we do not have any analyst data for this ticker
We cannot find data for Swedish Orphan Biovitrum 10 years ago, but if you had invested on Monday 2nd of December 2019 when the price was $16.75, you would have made a profit of $11.55 per share or 68.96%
No, the average daily trading liquidity for Swedish Orphan Biovitrum is $188 thousand. Trading in stocks with this little trading liquidity is very dangerous, and you can get into a situation where it will be hard to trade your stocks. In addition, these types of stocks usually have very high volatility.
Swedish Orphan Biovitrum has a normal ratio of the business financed by loans. This puts the company at some risk in periods of high inflation where borrowing costs usually go up. With a normal cash flow to debt ratio of 0.39, the company's ability to pay off the debt is normal. Swedish Orphan Biovitrum has a good net profit margin of 13.82% and should have high tolerances against inflation.
We have calculated the inflation risk for Swedish Orphan Biovitrum to be low [0.4 of 1]
US inflation for August 2024 was 0.19%. Over the last 12 months, the US inflation is 2.59%. The 10-year treasury yield that indicates the future interest level is currently 4.41 and is up 0.05 over the last 30 days.